PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects.

In contrast to evolocumab, the reduction in risk of venous thromboembolism by alirocumab did not reach statistical significance (hazard ratio 0.67 [95% CI, 0.44–1.01]).

also in 111,027 other papers

In the contrary, all-cause mortality was significantly lower under alirocumab, however, this finding is considered nominally significant as to the hierarchical testing with previous non-significant endpoints.

also in 7,732 other papers